【制药网 行业动态】在全球生物医药产业竞争日益激烈的当下,中国创新药企正以惊人的速度崛起,用实力在国际舞台上占据一席之地。近一个月以来,国产创新药海外授权热潮涌动,巨额交易接连不断,在医药行业与资本市场激起千层浪,向世界展现出中国医药创新的强劲动能。5月20日,三生制药宣布与全球制药头部辉瑞就自主研发的PD-1/VEGF双特异性抗体SSGJ-707达成一项总金额高达60.5亿美元的授权合作协议,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.